Pneumagen is developing Neumifil, a multivalent Carbohydrate Binding Module (mCBM) designed for the prophylaxis and treatment of viral respiratory tract infections, including influenza and coronaviruses. This targeted approach addresses the significant medical need for effective prevention of viral-induced exacerbations in patients with chronic respiratory diseases, which can lead to increased morbidity and healthcare costs.
Funding
$28.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic respiratory diseases are highly susceptible to viral respiratory tract infections, which frequently lead to exacerbations, accelerated decline in lung function, increased morbidity, and higher healthcare costs. Currently, there are limited treatments specifically designed to prevent these viral-induced exacerbations.
Solution
Pneumagen is developing Neumifil, an intranasal drug based on a multivalent Carbohydrate Binding Module (mCBM), designed for both the prophylaxis and treatment of a broad spectrum of viral respiratory infections. Neumifil targets common respiratory viruses, including influenza, respiratory syncytial virus, human rhinovirus, and coronaviruses like SARS-CoV-2. In a Phase 2 human challenge study, Neumifil demonstrated a statistically significant reduction in the incidence and severity of symptomatic influenza infection compared to placebo, with no new safety concerns identified. Pneumagen plans to advance Neumifil into further clinical studies, including evaluating its ability to reduce viral-induced exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
Target Audience
The primary target audience includes at-risk patients with chronic respiratory diseases such as COPD, bronchiectasis, and asthma, who are vulnerable to viral respiratory tract infections and associated exacerbations.
Features
- Broad-spectrum antiviral activity against a range of respiratory viruses.
- Intranasal administration for targeted delivery to the respiratory tract.
- Multivalent Carbohydrate Binding Module (mCBM) technology.
- Demonstrated reduction in symptomatic influenza infection in a Phase 2 human challenge study.